Specialities Inc. Introduces Hollandic
MILLINGTON, N.J.--(BUSINESS WIRE)--Jun 13, 2025--
Hollandic is how we say Gouda cheese!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613947667/en/
We are thrilled to introduce Hollandic, our exquisite Gouda cheese that brings a slice of the Netherlands to your table! Revered as one of the world's oldest cheeses, Hollandic is crafted from premium cow's milk, resulting in a semi-hard cheese that is rich in flavor and boasts a wonderfully creamy texture. Dutch Gouda stands out for its exceptional quality and rich heritage, making it a beloved choice for cheese aficionados around the globe.
Our Hollandic Gouda selection features a delightful variety, ranging from young and mild to intensely aged, each showcasing its distinct taste and character. Perfect on its own or as the star of a vibrant charcuterie board, Hollandic Gouda is the ideal addition to your culinary adventures!
Since 1991, Specialities Inc. has been at the forefront of importing, distributing, and elevating specialty food products across U.S. Deli and Specialty Markets, along with select food service distributors. Our 'Best of Class' offerings originate from both domestic and international artisans.
Please join us on June 28-30, 2025, at the New York Fancy Food Show Booth 468 to learn more about these all-natural and innovative products.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250613947667/en/
CONTACT: Ron Schinbeckler, Specialities Inc.
(908) 294-3200, (908) 647.6485
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK NEW JERSEY
INDUSTRY KEYWORD: SUPERMARKET RETAIL SPECIALTY FOOD/BEVERAGE
SOURCE: Specialities Inc.
Copyright Business Wire 2025.
PUB: 06/13/2025 08:06 PM/DISC: 06/13/2025 08:05 PM
http://www.businesswire.com/news/home/20250613947667/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
MAHWAH, N.J., June 16, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC); compared to the active ingredient in Pataday®2 Once Daily Relief. According to Nielsen® syndicated data for the latest 52-week period ending May 17, 2025, the Pataday® Once Daily Relief (OTC) market3 achieved annual sales of approximately $50.0 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers." For product information and how to purchase, please visit: About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma). References 1 Glenmark's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label. 2 This product is not manufactured or distributed by Alcon Laboratories, Inc., distributor of Pataday® Once Daily Relief, and/or Novartis AG, owner of the registered trademark Pataday®, respectively. [Neither Alcon nor Novartis make or license Glenmark's product.] 3 Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *Nielsen® NIQ Discover; Syndicated Data for Period Ending May 17, 2025 Logo: View original content: SOURCE Glenmark Pharmaceuticals Ltd Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Integris Amplifies Position as a Leading Future-Ready MSP with Strategic Acquisition
National managed IT services provider advances vision for differentiated service offerings and organizational growth with expanded footprint CRANBURY, N.J., June 16, 2025 /PRNewswire/ -- Integris, a national leader in future-ready managed services, backed by OMERS Private Equity, today announces the acquisition of premier managed service provider, TechMD along with its security division, 1nteger Security. This strategic acquisition is its largest to date and signifies the next pivotal milestone in Integris' continued evolution by expanding the company's innovative solutions and services that drive digital maturity for small to midsize businesses. "Every acquisition we make is a strategic step toward our vision of transforming Integris into a smarter, faster, and more transformative digital powerhouse," said Glenn Mathis, newly appointed CEO, and previous president and COO, of Integris. "By bringing like-minded teams and capabilities into the Integris family, we're not just expanding our footprint—we're deepening our ability to elevate the customer experience. Together, we will deliver a high-impact platform that's more responsive, more secure, and more aligned with the real needs of our clients." Founded in 1986 as ICS and rebranded to TechMD in 2023, the Northeast-based managed service provider—with a strong presence in California—has been helping small to midsize businesses and organizations power their success through technology for more than 20 years. This extensive knowledge and expertise in providing IT managed services, cybersecurity services, technical services, cloud solutions and product procurement will assist in advancing Integris' vision for the future of the industry. "Our mission has been to develop a technology company that is future-ready and forward-thinking with a strong sense of duty toward the customer experience, and we believe Integris is the perfect representation of this direction," said Kevin Blake, president and CEO of TechMD. "Integris and its leadership are in the right position to elevate our combined experience and technology solutions to the next level, and we're thrilled to be joining their team." This pivotal moment in Integris' history also marks the progression of leadership for the company. After founding and leading the company since its inception, Rashaad Bajwa is transitioning from CEO to executive chairman of the Integris Board. "It has been the privilege of my life to help build Integris into what it is today, however, I cannot think of a more perfect fit for the future of Integris than Glenn," said Bajwa. "Our industry is undergoing exciting changes, with Integris at the forefront of this innovative charge, and with Glenn's powerful thought leadership on how AI, automation and data will transform the MSP of the future, now is the perfect time for him to take over the reigns as CEO and for me to help support Integris from my position on the Board." To learn more about Integris' suite of solutions and services, visit Guggenheim Securities, LLC acted as exclusive financial advisor to TechMD. About IntegrisIntegris is a national leader in future-ready managed services, delivering innovative solutions that drive digital maturity for small to midsize businesses. We go beyond traditional IT management by delivering strategic roadmaps that optimize operations, strengthen cybersecurity, refine cloud solutions, and ensure compliance—all while enhancing our client's digital capabilities. Our goal is to transform each organization into a smarter and faster digital powerhouse. Our platform is responsive, secure, and ready to meet the unique regulatory demands of the industries we serve. Regularly featured on the Inc. 5000 list of fastest-growing companies, Integris is backed by the private equity arm of the Ontario Municipal Employees Retirement System (OMERS). For more information, visit About OMERSOMERS Private Equity manages investments globally on behalf of OMERS, one of Canada's largest defined benefit pension plans, with C$138.2 billion in net assets as of December 31, 2024, including approximately C$27.5 billion in net private equity investment asset exposure. The Buyout team invests across Industrials, Healthcare, Business Services and Technology, deploying an evergreen capital base to partner with strong management teams and transform good companies into industry leaders. For more information, please visit View original content to download multimedia: SOURCE Integris
Yahoo
2 hours ago
- Yahoo
Axia Women's Health Appoints Kyle Snook as Chief Executive Officer
VOORHEES, N.J., June 16, 2025 /PRNewswire/ -- Axia Women's Health (Axia), one of the nation's largest independent women's health groups, announced today the appointment of Kyle Snook as the company's new Chief Executive Officer, effective June 16, 2025. Mr. Snook succeeds Gaurov Dayal, MD, who moved into a Board of Directors role in January. "Kyle is an outstanding leader who brings a proven track record of driving growth, operational excellence, and profitability for independent physician practices," shared Eileen Auen, lead Board Director for Axia Women's Health. "His deep technical experience and commitment to expanding access to care, especially for vulnerable populations, make him an excellent fit." Mr. Snook joins Axia from PRISM Vision Group, a leading ophthalmology administrative services organization with over 100 affiliated locations, where he served as Chief Operating Officer. Prior to his time at PRISM, he held senior leadership roles at Strive Health and DaVita. Mr. Snook has a bachelor's degree in engineering from West Point and an M.B.A. from Harvard Business School. Kyle served in the U.S. Army as a Combat Platoon Leader with the 101st Airborne Division and earned a Purple Heart for his service in Afghanistan. Sujit John, Managing Director, Private Equity Health and Life for Partners Group, a majority investor in Axia Women's Health, added, "We're thrilled to have Kyle leading Axia Women's Health during this critical stage of growth. His leadership will be instrumental as we expand Axia's reach and bring high-quality care to even more women across the country." "I'm honored to join Axia, an organization with such a strong legacy of best-in-class women's healthcare," Mr. Snook said. "I'm looking forward to building on this foundation and working alongside our dedicated clinical and executive leadership team to further Axia's growth." About Axia Women's Health Axia Women's Health is one of the largest privately owned women's health groups in the country serving over 500,000 women throughout New Jersey, Pennsylvania, Indiana, and Kentucky. At its core, Axia is a community of 400+ providers across 100+ locations committed to providing a more caring, connected, and progressive healthcare experience for women. Axia connects its patients to a full spectrum of services including obstetrics, gynecology, fertility, maternal fetal medicine, mammography, behavioral health and laboratory services. Learn more at Media Contact:Chrissy View original content to download multimedia: SOURCE Axia Women's Health Sign in to access your portfolio
